Clinical Trial Update: A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC) [Phase 1]

View source ↗

Summary

Phase Ib trial of stereotactic body radiotherapy plus sorafenib for unresectable hepatocellular carcinoma has been withdrawn. The study status indicates it is n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: Indiana University | Conditions: Hepatocellular Carcinoma | Phase 1 | Status: WITHDRAWN